Goldman Sachs analyst David Roman initiates coverage on $Tandem Diabetes Care (TNDM.US)$ with a hold rating, and sets the target price at $46.
According to TipRanks data, the analyst has a success rate of 68.0% and a total average return of 4.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Tandem Diabetes Care (TNDM.US)$'s main analysts recently are as follows:
The outlook for insulin pump adoption within the Type 1 diabetes demographic is positive, which is expected to support further market share gains for Tandem Diabetes, bolstered by forthcoming product cycles. Nevertheless, current projections seem to already reflect this optimistic growth trajectory, with additional upside potentially hinging on increased Type 2 diabetes adoption, more significant market share advancements, or a hastened path to profitability.
The significant upside potential for Tandem Diabetes is anticipated due to earnings revisions and multiple expansion. The expected earnings increase is likely to stem from the adoption of Mobi, integration with continuous glucose monitoring systems, and the expansion of Type 2 indications, which could contribute to acquiring new patients and pump renewals. Despite the presence of weight loss drugs, Tandem's global pump market opportunity remains largely untapped.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
高盛集團分析師David Roman首次給予$Tandem Diabetes Care (TNDM.US)$持有評級，目標價46美元。
根據TipRanks數據顯示，該分析師近一年總勝率為68.0%，總平均回報率為4.7%。
此外，綜合報道，$Tandem Diabetes Care (TNDM.US)$近期主要分析師觀點如下：
在即將到來的產品週期的推動下，1型糖尿病人群採用胰島素泵的前景樂觀，預計這將支持串聯糖尿病市場份額的進一步增長。儘管如此，目前的預測似乎已經反映了這種樂觀的增長軌跡，額外的上行空間可能取決於2型糖尿病採用率的增加、更顯著的市場份額增長或盈利之路的加快。
由於收益調整和多次擴張，預計 Tandem Diabetes 具有巨大的上行潛力。預期的收益增長可能源於Mobi的採用、與持續血糖監測系統的整合以及2型適應症的擴大，這可能有助於吸引新患者和續訂新藥物。儘管存在減肥藥物，但Tandem的全球泵市場機會仍基本上未被利用。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
